Regarding the Bondlido US sales partnership, the sales license agreement is expected to be signed in September, with\u4e0a\u5e02 timing anticipated in Q4 2026. The contract term revisions are taking time, and the impact is considered minor.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4586","jir_company_name":"MedRx, Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-31","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4586-20260831-01.pdf","jir_short_summary":"Regarding the Bondlido US sales partnership, the sales license agreement is expected to be signed in September, with\u4e0a\u5e02 timing anticipated in Q4 2026. The contract term revisions are taking time, and the impact is considered minor.","jir_summary":"### Section Heading\nThis is a progress report on the Bondlido sales partnership and\u4e0a\u5e02 timing in the US market. The signing of a sales license agreement with Terrain Pharmaceuticals is progressing with a September expectation, and ongoing review of sales strategy, supply planning, and contract terms. Bondlido is expected to serve as a new patch alternative to Lidoderm, with potential competitive advantage in the US market. Impact on the company\u2019s FY2026 (year ending December 2026) is expected to minor.\n\n### Section 2 Heading\nAs the US lidocaine patch market expands, the aim is to penetrate the over-the-counter analgesic space using Terrain's nationwide distribution network. Although negotiations on contract terms are delayed, there is no\u4e0a\u5e02 timing change, and US market launch is anticipated. The focus going forward is finalizing the contract and supply plan.","jir_financial_highlights":"Impact on performance from Bondlido sales partnership: Unknown (Unknown)","jir_category":"","jir_hashtags":"#Bondlido, #USMarket, #Partnership, #SalesLicenseAgreement","jir_key_figures":"Bondlido sales partnership agreement signing timing: September expectation\nIPO timing: expected in Q4 2026\nImpact on FY2026: minor","jir_meta_title":"MedRx Bondlido US Sales Partnership Expected to Sign in September,\u4e0a\u5e02 in 2026 Q4\uff5cTerrain","jir_meta_description":"MedRx is progressing Bondlido's US sales partnership with Terrain, with a sales license agreement expected to be signed in September.\u4e0a\u5e02 timing is projected for 2026 Q4. While contract term revisions are taking time, impact on FY2026 is anticipated to be minor.","jir_og_title":"Bondlido US Sales Partnership; September Contract Signing Expected\uff5c Progress with Terrain","jir_og_description":"Bondlido US sales partnership is expected to sign in September,\u4e0a\u5e02 in 2026 Q4. Although contract term adjustments are taking time, impact is considered minor. Terrain plans to utilize nationwide distribution network.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59495,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"corporate_restructuring","footnotes":""},"sector":[],"importance":[],"class_list":["post-108656","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n